Manejo y prevención de efectos secundarios al empleo de un anticuerpo monoclonal inhibidor de la señal de los receptores del factor de crecimiento epidérmico

Abstract

Over the last decade, new anticancer therapies have been introduced, many of which have skin implications associated with different mechanisms of action. The antibody against the epidermal growth factor receptor (EGFR) represents one of the advances in the management of colorectal and head and neck cancer. The effects caused by this mediciation at the cutaneous level used to limit its use, since as its effectiveness is dose-dependent, doses had to be modified, and there was also poor physical and cosmetic tolerance by the patients. Today, the effects are properly managed; however now we must consider prophylaxis in order to reduce the degree of skin involvement.